Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : AP-HP
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, One Biosciences will leverage the data to identify new therapeutic targets in this rare kidney disease in order to develop precision medicines and biomarkers of a relapse of the disease via its discovery platform.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
November 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : AP-HP
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Antisense Oligonucleotide-based Therapy
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : Chinook Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The companies will leverage Chinook’s precision medicine approach and expertise in nephrology and Ionis’ expertise in RNA-targeted therapeutics for discovery, development and commercialization of an antisense oligonucleotide therapy for a rare, sever...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 16, 2023
Lead Product(s) : Antisense Oligonucleotide-based Therapy
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : Chinook Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : Hoxton Ventures
Deal Size : $8.6 million
Deal Type : Financing
Details : The net proceeds of the financing round will be used to to discover precision medicines for metabolic syndrome-related conditions and to demonstrate proof-of-concept for MultiOmic’s MOHSAIC® platform in diabetic kidney disease.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : Hoxton Ventures
Deal Size : $8.6 million
Deal Type : Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Collaboration
Evotec and Lilly Enter Into Drug Discovery Collaboration in Metabolic Diseases
Details : Under the agreement, Evotec will be responsible for the discovery of drug candidates for the treatment of diabetes and chronic kidney diseases from targets identified by Lilly or Evotec. Lilly reserves the right to select upto five programmes developed w...
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : $1,000.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : Harvard University
Deal Size : Undisclosed
Deal Type : Collaboration
Harvard University and Kyowa Kirin Enter Strategic Research Alliance
Details : The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : Harvard University
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : ARCH Venture Partners
Deal Size : $51.0 million
Deal Type : Series A Financing
Walden Biosciences Launches to Transform the Treatment of Kidney Disease
Details : Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
October 06, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : ARCH Venture Partners
Deal Size : $51.0 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : DCVC Bio
Deal Size : $33.0 million
Deal Type : Series A Financing
Details : The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : DCVC Bio
Deal Size : $33.0 million
Deal Type : Series A Financing